The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26, 2025. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and ...

b Performed 3 months later at the outpatient clinic. c For conversion to mg/dl divide by 0.0555. d For conversion to mg/dl divide by 88.4. a Performed at presentation. b Performed 3 months later ...

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26, 2025. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025. The FDA granted priority review to a supplemental new ...

Possible causes of low blood pressure, or hypotension, range from dehydration to a heart condition. Drinking more water may help, but some people will need medication. Changing dietary habits may ...

Genes that are as yet unidentified will probably be found to cause hereditary pheochromocytoma or paraganglioma and increase the proportion of hereditary cases above that which has been already ...

pheochromocytoma, paraganglioma (glomus jugulare tumor), pancreatic neuroendocrine tumor, endometrial cancer, rhabdomyosarcoma, non-rhabdomyosarcoma, Wilms' tumor (nephroblastoma), Ewing sarcoma, ...

Recently case reports have appeared in which both benzodioxane and dibenamine were effective in lowering the blood pressure to normal in a patient subsequently proved to have a pheochromocytoma.

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Pheochromocytoma. According to GlobalData, Phase II drugs for Pheochromocytoma have a 33% phase ...